Novel mechanism and biomarker of chronic progressive multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Chemokines in chronic progressive neurological multiple sclerosis
Chemokines are 8 ± 12 kd chemoattractant cytokines characterized by a four cysteine motif (Luster, 1998; Ransohoff et al, 1996; Schall, 1994; Taub, 1996). The presence or absence of an intervening amino acid(s) (X) between the N terminal cysteines de®nes the CXC/CX3C and CC families, respectively. A third family, C chemokines, lacks an N terminal cysteine but is otherwise homologous. It was ori...
متن کاملBiomarker efficacy in multiple sclerosis diagnosis and treatment
The goal in studies concerning biomarkers in autoimmune diseases is finding a marker which fluctuates in correlation with the disease’s severity and settles within normal borders after effective treatment. This marker would later be used as an efficient tool in diagnosis and analysis of medicine clout. It seems the most cogent biomarkers are those measurable in serum or plasma. MS is a neurolog...
متن کاملSerum and Saliva Myelin Basic Protein as Multiple Sclerosis Biomarker
Objective: Multiple sclerosis (MS) is presented with motor and sensory function loss. It is caused by demyelination and following axonal lesion. As myelin basic protein (MBP) is one of the key elements of the myelin cover, we examined the level of MBP in serum, stimulated, and unstimulated saliva as a suitable biomarker for detecting MS. Methods: A case-control study was performed in 29 health...
متن کاملChronic Progressive Multiple Sclerosis – Pathogenesis of Neurodegeneration and Therapeutic Strategies
Multiple sclerosis (MS) is an inflammatory, autoimmune, demyelinating disease of the central nervous system (CNS) that usually starts as a relapsing-remitting disease. In most patients the disease evolves into a chronic progressive phase characterized by continuous accumulation of neurological deficits. While treatment of relapsing-remitting MS (RRMS) has improved dramatically over the last dec...
متن کاملSafety, tolerability and pharmacodynamics of a novel immunomodulator, MIS416, in patients with chronic progressive multiple sclerosis
BACKGROUND Preclinical studies have demonstrated that MIS416, a bacterially derived immune modulator, targets myeloid cells following systemic delivery. MIS416 stimulated myeloid cells have the capacity to regulate innate inflammation, a potential therapeutic target for progressive multiple sclerosis. OBJECTIVES To determine the safety, tolerability, pharmacodynamics and maximum tolerated dos...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical and Experimental Neuroimmunology
سال: 2018
ISSN: 1759-1961
DOI: 10.1111/cen3.12449